Rosiglitazone, one of thiazolidinedione drug used for the treatment of type 2 diabetes, has a potential effect on insulin resistance through PI3K signaling pathway [16,17] to regulate expression and activation of IRS 1/2, GluT4 , PPAR-γ, PI3K and AKT to increases insulin stimulated glucose transport [18]. The gene discussed is SLC2A4; the disease is type 2 diabetes mellitus.